Finasteride/tadalafil
Combination drug
From Wikipedia, the free encyclopedia
Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH).[1][2][3] It contains finasteride and tadalafil.[1] It is taken by mouth.[1]
Trade namesEntadfi
| Combination of | |
|---|---|
| Finasteride | 5α-reductase inhibitor |
| Tadalafil | Phosphodiesterase 5 (PDE5) inhibitor |
| Clinical data | |
| Trade names | Entadfi |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
It was approved for medical use in the United States in December 2021.[1][4]
Medical uses
Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men.[1]
